REGISTER
Hansoh Licenses Oral IL-23 Drug in Deal Worth Up to $2.3B Tied to Avere–NextCure Merger
China-based Hansoh Pharmaceutical will license oral IL-23 receptor antagonist HS-20118 to Avere Therapeutics in a deal worth up to $2.3 billion, with the candidate set to reach the US through a reverse merger with Nasdaq-listed NextCure (expected ticker AVRX, closing in H2 2026). Phase 1 data reported at the SID annual meeting showed a 75% PASI75 and 87.5% IGA 0/1 response at week 8 in plaque psoriasis. The results have not been peer-reviewed.

Lead

China-based Hansoh Pharmaceutical is moving an experimental oral IL-23 receptor antagonist into US public markets through a reverse merger with Avere Therapeutics and Nasdaq-listed NextCure, the latest in a string of cross-border deals that combine licensing, equity, and a backdoor listing into a single transaction.

The Deal

The asset at the center of the deal, HS-20118 - to be known overseas as AVR-001 - is an oral peptide designed to block the IL-23 receptor, the same target addressed by injectable biologics such as Johnson & Johnson's guselkumab (Tremfya) and AbbVie's risankizumab (Skyrizi), as well as the recently approved oral icotrokinra.

Under the agreement, Avere will obtain exclusive global development, manufacturing, and commercialization rights to HS-20118 outside of mainland China, Hong Kong, Macau, and Taiwan. The licensing package carries a $120 million upfront payment and up to $2.18 billion in development and sales milestones - putting the headline value of the deal at roughly $2.3 billion - together with mid-single-digit to low-double-digit royalties on future net sales.

The asset will reach public markets through a reverse merger with NextCure. The combined entity plans to operate under the ticker AVRX on Nasdaq, with Hansoh holding an estimated 30% to 40% stake on a fully diluted basis. Hansoh will be entitled to nominate two of five board seats in the new entity. The transaction, expected to close in the second half of 2026, will be accounted for using the equity method and is not expected to be consolidated into Hansoh's financial statements.

A $320 million private placement will support the transaction, with $251 million structured as convertible notes that will convert into common stock at closing. The placement is led by Fairmount and Hansoh, with participation from Venrock Healthcare Capital Partners, General Atlantic, Wellington Management, and RTW Investments.

Use of proceeds is tied to clinical development: reading out a global Phase 2b trial in moderate-to-severe plaque psoriasis in the first half of 2028, initiating a subsequent Phase 3 program in psoriasis, and starting a Phase 2b program in ulcerative colitis.

An Early Clinical Signal

The clinical data supporting HS-20118 come from a Phase 1 trial in moderate-to-severe plaque psoriasis, reported at the Society for Investigative Dermatology (SID) annual meeting earlier this year. At week 8, patients who received 25 mg once daily recorded a PASI75 response rate of 75.0% and an IGA 0/1 response rate of 87.5%, according to the presentation. Hansoh has described the magnitude of the response as consistent with that seen in pivotal studies of approved IL-23 monoclonal antibodies.

Several caveats apply. The data have been presented at a scientific meeting only and have not yet been peer-reviewed. The Phase 1 sample size, full dosing arms, and analysis details have not been disclosed. No head-to-head comparisons with icotrokinra or with established IL-23 biologics have been reported, and longer-term efficacy and safety beyond week 8 remain unknown. The half-life of approximately 100 hours cited by Hansoh, which would support once-weekly dosing, also awaits confirmation in larger trials.

Why It Matters

The deal reflects a broader shift in how China's drug developers are approaching overseas markets. Hansoh has signed license or partnership deals with GlaxoSmithKline, Merck, Regeneron, and Roche between late 2023 and 2025 for ADCs, peptides, and small molecules in oncology and metabolic disease. The HS-20118 transaction layers equity and a Nasdaq listing onto a licensing framework, and Hansoh has positioned the structure as a template for future launches of its immunology and metabolic assets.

The broader market backdrop is large but uncertain. Third-party analysts cited in industry reports put the global oral IL-23 receptor antagonist market at roughly $7.5 billion in 2025 and project it to reach $27.3 billion by 2034, a 15.8% compound annual growth rate. Those figures were not independently validated by the deal parties and combine multiple modalities and indications.

China's national out-licensing activity has accelerated in parallel. According to data from China's National Medical Products Administration (NMPA), Chinese developers completed 81 out-licensing transactions for innovative drugs in the first half of 2026, totaling approximately $110 billion in deal value and reaching roughly 80% of the 2025 full-year total, with deals increasingly extending beyond oncology into autoimmune and metabolic disease.

The Competitive Picture

The oral IL-23 field has just gained its first commercial entrant. Icotrokinra, a macrocyclic peptide developed by Johnson & Johnson, received FDA approval in March 2026 for moderate-to-severe plaque psoriasis, becoming the first oral IL-23 receptor antagonist cleared in the US. In its registrational program, icotrokinra achieved a Week 16 IGA 0/1 response of 64.7% and a PASI 90 response of 49.6%, with once-daily dosing. HS-20118's longer apparent half-life and proposed once-weekly schedule could, if confirmed in later-stage trials, offer a more convenient dosing option - though any meaningful judgment on differentiation awaits the Phase 2b readout in 2028 and beyond.

Hansoh is not alone in the Chinese oral IL-23 peptide field. Haisco Pharmaceutical's HSK47388 is reported to be in Phase 2 development, according to industry tracking.

The broader deal also offers a window onto Avere Therapeutics and its leadership. Avere's chief executive, Andrew Cheng, previously led Akero Therapeutics, a MASH-focused biotech acquired by Novo Nordisk in December 2025 for approximately $5.2 billion. NextCure itself is a small Nasdaq-listed clinical-stage company whose longer-term operating footprint and pipeline remain limited.

Limitations

Closing of the reverse merger and the private placement remains subject to customary regulatory and shareholder approvals, and trading under the AVRX ticker has not yet commenced. The candidate's clinical signal is supported only by an early-phase, non-peer-reviewed dataset, and any conclusions about efficacy, safety, or differentiation versus icotrokinra or injectable IL-23 biologics must await the Phase 2b data readout planned for the first half of 2028.

0
0
Loading